Indeed, the injection of tumor-derived MV to reach 10-fold higher plasma levels of MV-TF activity than the levels measured in pancreatic tumor-bearing mice was necessary to obtain an increase in plasma platelet factor 4 [23], suggesting that platelet activation might not be a major mechanism in the pathophysiological of PDAC-associated VTE. Here, PF4 is linked to neoplasm.